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Abstract 
 
The bile salt export pump (BSEP) is an ABC-transporter expressed at the canalicular 
membrane of hepatocytes. Its physiological role is to expel bile salts into the canaliculi from 
where they drain into the bile duct. Inhibition of this transporter may lead to intrahepatic 
cholestasis. Predictive computational models of BSEP inhibition may allow for fast 
identification of potentially harmful compounds in large databases. 
This article presents a predictive in silico model based on physico-chemical descriptors that is 
able to flag compounds as potential BSEP inhibitors. This model was built using a training set 
of 670 compounds with available BSEP inhibition potencies. It successfully predicted BSEP 
inhibition for two independent test sets and was in a further step used for a virtual screening 
experiment. After in vitro testing of selected candidates, a marketed drug, bromocriptin, was 
identified for the first time as BSEP inhibitor. This demonstrates the usefulness of the model 
to identify new BSEP inhibitors, and therefore potential cholestasis perpetrators. 
 
 
Keywords 
BSEP, classification model, inhibition, drug-induced cholestasis, bromocriptin 
 
 
Introduction 
 
The bile salt export pump (BSEP; gene name ABCB11) is a member of the subfamily B of ABC 
transporters. It is expressed in the liverat the canalicular membrane of the hepatocytes. It 
transports bile salts from the hepatocytes into the bile using the energy provided by ATP 
hydrolysis. The main substrates of BSEP are monovalent conjugated bile acids such as 
taurochenodeoxycholate 1. However, drugs such as pravastatin have also been shown to be 
transported by BSEP (although with low affinity and therefore without in vivo impact) 2. 
Impairment of BSEP expression or function due to mutations in the ABCB11 gene 
leads to progressive familial intrahepatic cholestasis type 2 (PFIC2) 3. PFIC2 is an autosomal 
recessive condition which starts at early childhood with mild cholestasis, but develops in 
more critical liver failures and may necessitate liver transplantation at later stages. 
Inhibition of BSEP by small molecules may also impair its function. As a result, efflux 
of bile salts decreases, leading to their accumulation inside the hepatocytes and, 
consequently, to drug-induced liver injury (DILI) manifested as acquired intrahepatic 
cholestasis. Bosentan 4 and troglitazone 5 are two examples of drugs whose hepatotoxicity 
can be directly linked to an inhibition of BSEP. The latter was withdrawn from the market in 
2000 for its toxicity. 
While the Food and Drugs Administration (FDA) does not provide directives regarding 
the testing of drugs for their inhibitory activity on BSEP, the European Medicine Agency 
(EMA) suggests investigating potential inhibition of the transporter 
6,7
. In case in vitro studies 
reveal an inhibition, the serum bile salt levels should be monitored in vivo during later 
phases in the drug development process. In this scenario, a fast and inexpensive in silico pre-
screening of candidates could be useful in order to reduce the amount of in vitro tests 
needed. 
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There are few in silico models of BSEP inhibition available so far. The model of Hirano 
and colleagues 
8
 is based on a very small data set of 37 compounds and thus would not allow 
in silico profiling of chemically diverse compound libraries. Warner et al. 9 used a balanced 
training set of 437 compounds to build several classification models based on in-house 
descriptor sets, comprising 2D, 3D and fingerprint-like features. Their best model reached an 
accuracy of 0.87 (on a test set of 187 compounds). Finally, Pedersen and colleagues 10 built 
two orthogonal partial least-squares discriminant analysis (OPLS-DA) models on 163 
compounds. They report an accuracy of 0.89 on a test set of randomly selected 86 
compounds. However, none of these models were used in any prospective studies to 
identify new BSEP inhibitors and thereby demonstrate their performance in real life settings. 
In this study, we built a classification model based on a set of physico-chemical 
descriptors for predicting BSEP inhibition. The model revealed the importance of 
hydrophobicity, aromaticity and H-bond donor characteristics for separating inhibitors from 
non-inhibitors. It had an accuracy of 84% in ten-fold cross-validation, 80% in a randomly 
selected external set, and 88% in a validation set built on publicly available data. A 
subsequent screen of the DrugBank database revealed many drugs already known as BSEP 
inhibitors in the top-ranked positions. To further evaluate the prospective usefulness of the 
model, we selected compounds from the top-scoring ones for which up to now no BSEP 
inhibition information was available. Selection criteria comprised, among others: chemical 
diversity, known bile elimination or liver metabolism, and commercial availability. Finally, 
seven compounds were experimentally tested using two distinct in vitro systems: a 
membrane vesicle assay and a more complex Transwell® assay. This led us to identify 
bromocriptin, a currently marketed drug, as BSEP inhibitor. The model has been 
implemented as a KNIME workflow 12 which is available for download from the 
supplementary material. 
 
 
Material and methods 
 
The original data was donated by AstraZeneca within the framework of the IMI project eTOX 
(www.etoxproject.eu). It contained the BSEP inhibitory potencies reported as IC50 (µM) 
values of 1092 compounds provided as smile strings. Data was measured in a [3H]-
taurocholate transport assay performed in Sf21 membrane vesicles following the protocol in 
13. 
 
Database curation 
The initial dataset was curated using the procedure described in Pinto et al. 14. Briefly, it 
consists of the following steps: (1) removal of inorganic compounds (i.e. compounds not 
containing carbon atoms) using Instant JChem v.5.3, 2010, ChemAxon 
(http://www.chemaxon.com); (2) analysis and removal of mixtures formed by two or more 
large molecules; (3) deletion of organometallic compounds using MOE 2011.10 15; (4) 
identification and removal of compounds containing special atoms such as selenium or 
tellurium by means of an in-house MOE SVL script; (5) normalization of chemotypes using 
the ChemAxon’s Standardizer with the following settings: clean 2D, aromatize, mesomerize, 
neutralize, tautomerize and all transform options; (6) identification and elimination of non-
unique structures using MOE; (7) deletion of compounds having permanent charges. The 
application of this procedure led to a curated data set of 1048 compounds. 
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Compound labeling 
Compounds having an IC50 lower or equal to 10 μM were considered as inhibitors, whereas 
those having an IC50 higher than 50 μM were labeled as non-inhibitors. Compounds having 
activity values between 10 and 50 μM were not considered to build the classification models 
and were discarded. This procedure led to a final data set formed by 838 compounds, 563 of 
which were non-inhibitors and 275 were inhibitors. 
 
Descriptor calculation 
78 interpretable 1D and 2D descriptors representing physico-chemical properties were 
calculated using MOE2011.10 15. These descriptors were not selected based on information 
content or correlation with the dependent variable, but rather on their physico-chemical 
interpretability. The exact list of descriptors is available as supplementary information. 
Descriptors of the training set were Z-normalized using KNIME 12. Computed means and 
standard deviations were then applied to the different test sets (see below). 
 
Training and test set selection 
80% of each class was randomly selected for use as training set. The remaining compounds 
were considered as test set. The composition of the resulting sets is shown in Table 1. 
 
 Total Inhibitors Non inhibitors 
Complete dataset 838 275 563 
Training set 670 220 450 
Test set 168 55 113 
External set 156 39 117 
 
Table 1: Composition of the datasets in number of compounds 
 
 
External validation 
In order to assess the prospective predictive power of the model, an external validation was 
carried out using a data set compiled from the literature 
8,16
. Hirano et al. 
8
 tested 42 
compounds among neurotransmitters, calcium channel blockers, potassium channel 
modulators, steroids, non-steroidal anti-inflammatory drugs, anticancer drugs, and others. 
The percentage of inhibition of BSEP at 100 µM was measured (in comparison with a 
negative control without test drug). The highest inhibition was obtained for nicardipine 
(100% inhibition), prenylamine (77% inhibition), fendiline (80% inhibition) and nifedipine 
(75% inhibition) from the calcium channel blockers, while the other compounds showed low 
to moderate inhibition (under 50%). Those were therefore not considered as inhibitors. 
Morgan et al. 16 measured the BSEP inhibition activity of 217 compounds to relate them with 
liver injuries. Compounds with IC50 below 25 µM were taken as inhibitors, while compounds 
with IC50 over 135 µM were taken as non-inhibitors. The 25 µM threshold was chosen 
because, among the compounds that were present both in the training set and in 16, the 
equivalent IC50 in the training set was usually below 10 µM. 
The chemical structures were retrieved by name from Pubchem Compound 
(http://www.ncbi.nlm.nih.gov/pccompound). This external set was curated using the same 
protocol as previously described. Those compounds also present in the AstraZeneca data set 
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were removed, leading to a final set formed by 156 compounds, 39 inhibitors and 117 non-
inhibitors. 
 
Model building 
The Weka 3.7.10 library 17 was used to build a set of classification models. The machine 
learning algorithms Naïve Bayes (NB), k-nearest neighbor (IBk), J48 and Random Forest (RF) 
were used with embedded attribute selection (CfsSubsetEval evaluator and BestFirst search). 
Additionally, in order to improve the performance of the models, optimization of the 
number of neighbors in IBk, the minimum number of instances per leaf in J48 or the number 
of trees in RF was performed using the CVParameter selection tool provided by Weka with 
an internal 5-fold cross-validation.  
The model showing best performance was implemented as a KNIME workflow 12. It is 
available for download in the supplementary information. KNIME is an Open Software 
platform used for implementing pipeline-like workflows. Here, the pipeline starts by reading 
the input dataset (as an sd file), then computes the required descriptors using the MOE 
node. The trained model is then read and the new compounds passed through, and the 
predictions (both as a score between 0 and 1 and as a binary outcome) are saved in a csv 
file. All necessary information to install and use the model is available in the Supplementary 
Information. However, a MOE license is required to calculate all descriptors needed. 
 
Virtual screening 
A total number of 1700 compounds were retrieved from the DrugBank database 
(www.drugbank.ca, 18) (as of October 2013) and curated using the same protocol as that 
described in the Database curation section. These compounds were passed through the 
model and ranked according to their predicted inhibitor score, which roughly corresponds to 
their probability of inhibiting BSEP according to the model. 
 
Chemical similarity 
Chemical similarity was measured by Tanimoto similarity on RDKit fingerprints 19. 
 
In vitro testing 
Materials 
[14C]-taurocholic acid and [3H]-taurocholic acid were purchased from American Radiolabeled 
Chemicals, Inc. (St. Louis, MO, USA). Taurocholic acid was obtained from ICN Biomed, Inc. 
(Irvine, California, USA). Cyclosporin A, pioglitazone, taurocholate, ATP, Mg(NO3)2 and 
sodium butyrate were from Sigma (St. Louis, MO, USA). TRIS and Hepes were purchased 
from Roth (Karlsruhe, Germany), sucrose from neoLab (Heidelberg, Germany), and KNO3 and 
KCl from Merck (Darmstadt, Germany). All other compounds were obtained from Glentham 
Life Sciences Ltd (Wimbledon, London, United Kingdom). LLC-PK1 stable cell lines expressing 
BSEP and NTCP were generated in the laboratory of B. Stieger. The expression analysis of 
BSEP was performed by western blot analysis and is available as Supplementary Information. 
CHO Flip-In cells expressing NTCP were characterized in 20. The liquid scintillation fluid Filter 
Count, used in transport studies, was purchased from PerkinElmer (Waltham, MA, USA). 
 
Cell culture 
LLC-PK1 cells stably expressing BSEP and NTCP were cultured in DMEM (Life Technologies, 
Rockville, MD, USA) supplemented with 10% fetal calf serum (FCS), 2 μg/mL puromycin and 
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700 μg/mL G418. Chinese hamster ovary (CHO) Flip-In cell lines were cultured in Ham’s F-12 
medium (Gibco-Thermo Fisher Scientific, Waltham, Massachusetts, USA) containing 100 
IU/mL penicillin/streptomycin, 10% fetal calf serum, 1 mM l-glutamine. CHO WT cells were 
maintained in the presence of 0.1 mg/mL Zeocin (Invitrogen, Waltham, Massachusetts, USA) 
whereas CHO-NTCP cells were cultured with 0.5 mg/mL hygromycin B (Invitrogen, Waltham, 
Massachusetts, USA). All cells were cultured at 37°C in an atmosphere containing 5% CO2 
with 95% relative humidity.  
 
Taurocholate transport studies in BSEP-expressing Hi5 membrane vesicles 
ATP-dependent uptake of [3H]-taurocholate by BSEP was measured using human BSEP-
expressing Hi5 membrane vesicles (Solvo, Budapest, Hungary) and the rapid filtration 
technique as previously described 20. Vesicles were diluted to a concentration of 2.5 µg/µL 
with 50 mM sucrose, 100 mM KNO3, 20 mMHepes/Tris pH 7.4; 10 µL of vesicles was pre-
warmed in a 37°C water bath for 30 sec, and uptake was initiated by the addition of 40 µL 
uptake buffer (50 mM sucrose, 100 mM KNO3, 12.5 mM Mg(NO3)2, 10 mMHepes/Tris, pH 
7.4) containing radiolabelled taurocholate (3 µCi/mL; final concentration in the assay 2.5 
µM). After 10 min of incubation in the 37°C water bath, transport was stopped by adding 3 
mL of ice-cold stop solution (50 mM sucrose, 100 mM KCl, 10 mM Tris/HCl, pH 7.4) and 
immediate filtration through 0.45 µm nitrocellulose acetate filter (Sartorius, Göttingen, 
Germany) pre-soaked with 1 mM taurocholate solution. The tube was rinsed once with 3 mL 
of cold stop solution and also filtered. After filter washing with 3 mL of ice-cold stop solution 
twice, the filter was dissolved in liquid scintillation fluid and radioactivity was measured in a 
Beckman Counter. For inhibition studies, the compounds were added to the uptake buffer to 
reach a final concentration of 10 µM. The final DMSO concentration in all samples was 0.8%. 
As recommended by the manufacturer, cyclosporin A was used as positive control at a final 
concentration of 20 µM. In addition, pioglitazone was used as positive control at a final 
concentration of 10 µM. To measure ATP-dependent taurocholate (TC) uptake, 5 mM ATP 
(final concentration in the assay) was added to the uptake buffer, and uptake rates were 
calculated as the difference in uptake in the presence and in the absence of ATP.  
Hi5-beta galactosidase membrane vesicles (Solvo, Budapest, Hungary) were used as negative 
control to measure endogenous TC transport of Hi5 membrane vesicles. 
 
IC50 determination of bromocriptin in BSEP-expressing Hi5 membrane vesicles 
ATP-dependent uptake of [3H]-taurocholate by BSEP was measured in absence and presence 
of 8 different concentrations of bromocriptin at an incubation time of 5 min as described in 
the section above. For IC50 measurements of bromocriptin, stock solutions were prepared by 
a 1:2.5 serial dilution in DMSO, resulting in final bromocriptin concentrations ranging from 
50 to 0.08 µM. Final DMSO concentration in all samples was 0.8 %. The uptake rates, 
calculated as the difference in uptake in the presence and in the absence of ATP, were 
plotted against the logarithmic concentration of bromocriptin in µM. IC50 values were 
calculated by nonlinear regression analysis using GraphPad Software Inc. (San Diego, CA, 
USA) Prism version 6.00 and the equation  
 
 
 
where a is the Hill Slope. 
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Taurocholate transport studies in LLC-PK1 NTCP- and BSEP-expressing cells 
The transcellular assay was set up following the methodology reported in Kagawa et al. 21 
with some modifications. Briefly, LLC-PK1 stable cell line expressing BSEP and NTCP were 
plated on a Transwell® membrane insert (no. 3470, diameter 6.5 mm, pore size 0.4 μm, 
Corning Costar, Cambridge, MA, USA) at a concentration of 2 x 105 cells/membrane. After 24 
h, the cells were treated with 5 mM sodium butyrate for further 24 h. To measure 
taurocholic acid transport activity, cells were washed twice with PBS and moved to DMEM 
(without FCS or antibiotic). Subsequently, the cells were incubated with pre-warmed basal 
medium containing 10 μM [14C]-taurocholic acid and pre-warmed apical compartment in the 
presence or absence of testcompounds. After 1 h incubation under humidified condition at 
37°C with 5% CO2, the apical medium was collected for measurement of the radioactivity 
using a scintillation counter (Tri-Carb 2100TR, PerkinElmer).  
 
Taurocholate transport studies in CHO NTCP-expressing cells 
[14C]-Taurocholic acid uptake and inhibition of NTCP were performed in CHO-WT and CHO 
Flip-In NTCP cells as described previously 
22
. Cells were plated at the density of 1 x 10
5 
cells/well onto 24-well plates. Twenty-four hours after seeding, the cells were treated with 5 
mM sodium butyrate and cell culture was pursued for further 24 h prior to the experiment. 
Before the uptake experiment, CHO cells were rinsed three times with 1 mL of pre-warmed 
uptake buffer and then pre-incubated in 500 µL of pre-warmed buffer before adding 
substrate. To measure Na-driven NTCP-mediated transport, two different uptake buffers 
were used either with sodium (116.4 mM NaCl, 5.3 mM KCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 
5.5 mM D-glucose, and 20 mM Hepes/Tris pH 7.4) or without (116.4 mM choline chloride, 
5.3 mM KCl, 1 mM KH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose, and 20 mM Hepes/Tris pH 
7.4). Taurocholic acid uptake was initiated by the addition of 500 µL pre-warmed uptake 
buffer containing 2.5 µM taurocholic acid (0.025 µCi/mL [14C]-taurocholic acid). After 5 min 
of incubation at 37° C, the uptake was stopped by removal of the uptake solution followed 
by washing 3 times with 1 mL ice-cold uptake buffer. The cells were then lysed in 500 µL of 
0.1 mM NaOH for at least 1 h at room temperature. The lysate suspension was used for 
radioactivity measurement by liquid scintillation counting.  
For the inhibition studies, the uptake was examined in the presence of positive control 
(cyclosporin A) or test compounds at a final concentration 10 µM. DMSO was adjusted to 1% 
as a control in all experiments. 
 
Statistical analysis 
Statistical analyses were performed by using unpaired, parametric t-test using GraphPad 
Software Inc. (San Diego, CA, USA) Prism version 6.00. Data were normalized to DMSO 
control, which was set as 100%. T-test was applied to compare each single compound with 
the DMSO control. 
 
 
Results 
 
Classification model 
As outlined in the methods section, a panel of classifiers was trained on a set of 670 
compounds in order to predict if a compound acts as BSEP inhibitor. The performance of the 
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best model, a Random Forest of 10 trees with integrated feature selection based on a set of 
78 1D and 2D descriptors, is reported in Table 2. A charged and a neutralized version of the 
training set were used and the neutralized version gave the best cross-validation results. 
 
 
 TN FN TP FP MCC ROC area 
10-fold CV 408 65 155 42 0.63 0.91 
5-fold CV 409 68 152 41 0.62 0.91 
Test set 97 18 37 16 0.54 0.87 
External set 108 9 30 9 0.69 0.92 
 
Table 2: Confusion matrix, Matthews correlation coefficient and area under the ROC curve 
for the cross-validation and test sets for the best model. 
 
On the basis of the features selected by the model (number of aromatic atoms 
(a_aro), number of triple bonds (b_triple), Van der Waals surface area of H bond donors 
(vsa_don), number of Br atoms (a_nBr), logP (logP(o/w)), Van der Waals surface area of 
hydrophobic atoms (vsa_hyd), number of C atoms (a_nC), number of rings (rings), molecular 
weight (weight)), hydrophobicity, the size of the molecule, the aromaticity and the number 
of hydrogen bond donors seem to play a critical role in BSEP inhibition. 
 
Virtual screening 
 Given the good performance of the model in internal and external validation, 
DrugBank was screened for potential BSEP inhibitors. For this, 1700 small molecules from 
the DrugBank database 18 were passed through the Random Forest and ranked by prediction 
score. This score takes values between 0 and 1, and the higher the score, the higher the 
probability of the compound to be a BSEP inhibitor according to the model. 59 compounds 
actually got the highest possible score, and were further investigated. Among them, 13 
compounds were labeled as inhibitors in the training set used to build the model. 10 others 
were reported in the literature or in DrugBank as inhibitors of BSEP but were not part of the 
training set. Irinotecan and atorvastatin were reported as non-inhibitorand inhibitor at 50 
µM, respectively 
10
. Since we used a threshold of 10 µM to define an active in the training 
set, we count both results as false positives. Tamoxifen and nelfinavir are inconsistently 
reported with both inhibitor and non-inhibitor activities 8,16,10,13. This leaves us with 32 
compounds that are top ranked and for which we could not find any pharmacological 
annotation regarding BSEP. 
A further analysis of the results of the screening for scores down to 0.8 (still predicted 
as inhibitors, but with less probability) retrieved 26 compounds with known BSEP 
annotation: 8 compounds that were present in the training set, 12 true positive (i.e. 
compounds found in literature to be inhibitors), 4 compounds with middle range activities 
and 2 false positive (i.e. compounds found in the literature to be non-inhibitors of BSEP). 
On the other hand, 1340 DrugBank small molecules received a score below 0.5, which is the 
threshold used for binary prediction. This means that the model predicts those compounds 
as non-inhibitors of BSEP. We studied these compounds and found 314 for which there was 
a pharmacological annotation available. 147 of them were actually part of the training set of 
the model (including 2 misclassified compounds), while 161 compounds were reported in 
the literature as non-inhibitors but were not part of the training set. Another 18 compounds 
had IC50 values over 10 µM but below 50 µM, and as such do not strictly count as errors 
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since we used 10 µM as a threshold to define the inhibitors in the training set. Finally, six 
compounds were mispredicted as non-inhibitors while they were actually reported as 
inhibitors: atazanavir 10,23, telithromycin 8,16, ranolazine 10, trovafloxacin 23, pioglitazone 13,9,16 
and diethylstilbestrol 10. This results in 161 true negatives and 6 false negatives, which 
corresponds to a negative predictive value of 96% (the negative predictive value is obtained 
by dividing the number of true negatives by the total number of predicted negatives). To 
compare with, the negative predictive value obtained for the 10-fold cross-validation was 
86%, 84% for the randomly selected test set and 92% for the external set. The positive 
predictive value for the top scoring compounds analyzed here is 0.73 (22 true positives and 8 
false positives). This value is lower than the one obtained for the external set (0.77), the 10-
fold cross-validation (0.79) but higher than the one of the randomly selected test set (0.70). 
 
In vitro testing 
Among the 32 compounds which received the highest score in the model and had no 
reported BSEP interaction in the literature, we eliminated one compound, halobetasol, 
which has topical application. Fourteen compounds that were not reported to undergo liver 
metabolism or elimination were removed. To ensure that compounds do not have a 
Tanimoto similarity > 0.75 to any other compound within the set or in the training set, we 
removed toremifene, which had a similarity of 0.94 with one compound of the training set. 
This led to a short list of 16 compounds, whereby 7 of them could finally be purchased. 
To directly assess BSEP inhibition, we used a membrane vesicle assay as 
recommended by the International Transporters Consortium 24. This kind of assay has the 
advantage of showing the direct impact of the test compounds on BSEP-mediated 
taurocholate (TC) transport. It is devoid of metabolism or permeability uptake problems. 
The obtained results at a single concentration of test compounds are reported in 
Figure 1. In addition to the positive controls cyclosporin A and pioglitazone, which indeed 
decreased TC uptake to 15 ± 3% and 8 ± 3% respectively, bromocriptin reduced BSEP-
mediated TC uptake significantly to 45 ± 10%. In contrast, raloxifen and vecuronium 
increased BSEP-mediated TC transport significantly to 125 ± 7% and 114 ± 7%, respectively, 
as compared to the DMSO control. All other compounds did not affect BSEP function. 
Vesicles which did not express BSEP were used as negative control to exclude TC transport 
by endogenously expressed transporters in Hi5 cells. Indeed, these vesicles showed only 3 ± 
1% of TC transport compared to vesicles expressing BSEP. 
The inhibitory activity of bromocriptin was studied in more detail by an IC50 value 
determination. As shown in Figure 2, an IC50 value of 1.2 ± 0.1 µM was evaluated. 
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Figure 1: Effect of different compounds on BSEP-mediated TC transport. ATP-dependent 
uptake of 2.5 µM TC in BSEP-Hi5 membrane vesicles was measured in absence (black bar) 
and presence of the test compounds (light grey) or known BSEP inhibitors (dark grey) as 
described in the materials and methods section. TC uptake data are given as the mean 
percentage of DMSO control ± SD of 3 independent experiments. Each experiment was 
performed in technical triplicates. Compounds showing significant different TC uptake as 
compared to DMSO control are marked with asterisks (*, p<0.05; **, p<0.01; ****p<0.0001). 
 
 
Figure 2: Effect of bromocriptin on BSEP-mediated TC transport. ATP-dependent uptake of 
2.5 µM TC in BSEP-Hi5 membrane vesicles was measured in absence and presence of eight 
increasing concentrations of bromocriptin as described in the Materials and Methods 
section. Data are given as the mean percentage of TC uptake compared to the DMSO control 
± SD of 3 independent experiments. Each experiment was performed in technical triplicates. 
 
 In an attempt to evaluate BSEP inhibition in a whole-cell system, we also tested the 
seven compounds in a transcellular flux assay. For this, we used LLC-PK1 cells expressing 
NTCP at the basolateral and BSEP at the apical membrane (see Supplementary Information, 
Figure SI-3). NTCP mediates the uptake of taurocholate from the basal compartment, while 
BSEP exports taurocholate into the apical medium. The final amount of transported 
substrate is measured from the apical compartment. The inhibition results at a single 
concentration (10 µM) of test compounds are shown in Figure 3. The positive controls, 
cyclosporin A and pioglitazone, showed lower taurocholate transport (42 ± 11% and 55 ± 
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18%, respectively). Bromocriptin was found again to cause a decreased transport of 
taurocholic acid (69 ± 5%). In addition, montelukast showed an inhibitory effect (57 ± 18%). 
 
 
Figure 3: BSEP inhibition study in a transcellular flux assay. Effect of known BSEPinhibitors 
(cyclosporin A and pioglitazone, dark grey bars) and test compounds (light grey) was studied 
using LLC-PK1 cells stably expressing BSEP and NTCP in a Transwell® system as described in 
the Materials and Methods section. Data show the amount of taurocholate in the apical 
compartment medium as a percentage of the DMSO control (absence of compound). Data 
are given as the mean percentage of taurocholate uptake compared to the DMSO control 
(black bar) ± SD of at least 3 independent experiments. Compounds showing significant 
different TC amount in the apical compartment as compared to DMSO control are marked 
with asterisks (**, p<0.01; ***, p<0.001). 
 
 
As previously described, the transcellular transport of taurocholate (TC) through a 
cell monolayer is mediated by the sodium-dependent TC uptake transporter NTCP at the 
basolateral side and the ATP-dependent TC efflux via BSEP at the apical side. As montelukast 
showed no inhibitory effect on BSEP in the vesicle assay, but showed inhibition of the 
transcellular flux of TC, we investigated the effect of the known NTCP inhibitor cyclosporin A 
as well as bromocriptin and montelukast on NTCP-mediated TC transport. Cyclosporin A 
shows a strong inhibition at 10 µM (13 ± 1%). Interestingly, montelukast also inhibits 
taurocholic acid uptake by NTCP (46 ± 7%), while bromocriptin shows no significant effect 
compared to the DMSO control (see Supplementary Information, Figure SI-4).  
 
 
Discussion 
 
After pharmacokinetics problems and lack of efficacy, the toxicity of compounds is a 
major cause of failures in late stages of drug development 25. In particular, DILI is the most 
frequent reason for withdrawal of approved drugs 26. Early identification of such problematic 
compounds must be a priority for obvious economic and social reasons.  
BSEP inhibition has been correlated with drug-induced liver injury (DILI) 13. As bile salt 
transporter localized at the canalicular membrane of hepatocytes, BSEP is the major 
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constituent to generate bile flow, mediating the transport of monovalent bile salts into bile 
27
. Any impairment of BSEP function results in bile acid accumulation and consequently liver 
injury due to the bile acid cytotoxicity 28,29,30,31,32,33,34,35. Dawson and colleagues 13 studied 
the relationship between drug-induced hepatotoxicity and the potency of BSEP inhibition for 
85 pharmaceuticals. They found out that all the 17 drugs in their dataset having an IC50 for 
human BSEP inhibition below 100 μM caused DILI. They also found that BSEP inhibitors tend 
to have high molecular weight and lipophilicity. Similar correlation was found by Pedersen 
and colleagues 
10
, where more than half of the BSEP inhibitors in their study were strong DILI 
inducers. 
To the best of our knowledge, three ligand-based models to predict BSEP inhibition 
have been reported so far 
8,9,10
. Briefly, Hirano and colleagues fitted a QSAR model to predict 
the percentage of inhibition by linear regression on 37 compounds 8. They report a R² of 0.95 
but did not perform a cross-validation to evaluate the predictivity of their model. More 
recently, Warner and colleagues used a larger dataset (437 compounds) to build a binary 
classification model to predict BSEP inhibition. The best external validation performance was 
obtained with support vector machine built on in-house descriptors (accuracy: 0.87, 
sensitivity: 0.9, specificity: 0.84) 
9
. Finally, Pedersen and colleagues performed partial least-
square discriminant analysis to classify BSEP strong inhibitors, weak inhibitors and non-
inhibitors 10. The best model was obtained when using only the two classes “strong 
inhibitors” versus “non-inhibitors”. In that case, the training set contained 142 compounds 
and the test set 74 compounds (accuracy: 0.89, sensitivity: 0.76, specificity: 0.94). 
Our own models were built on a significantly larger training set (670 compounds) and 
validated by cross-validation and external sets. The external validation gives an accuracy of 
0.88, sensitivity of 0.77 and a specificity of 0.92 (Table 2). This is equivalent to the values 
reported in 9,10. The high area under the ROC curve (AUC, around 0.9 for all validation 
schemes) shows a great capacity for our model at ranking compounds by their probability of 
being inhibitors of BSEP. The AUC is a good metrics for virtual screening applications and 
present the advantage of being independent from class distributions 11,36. 
The model is extremely fast (the longest step being the computation of the molecular 
descriptors) and can be used on a large number of compounds in a timely manner. As a 
reference, we needed around 2 min in a regular desktop computer to predict the 1700 
DrugBank compounds. The implementation into a KNIME workflow allows pipelining the 
whole process, so that there is no need to load the whole library of compounds in the 
memory. Instead, the molecules to predict are treated one by one, which allows to process 
libraries of any size. 
Such in silico models, because of their ability to treat millions of compounds in a 
timely manner, could in theory be used to pre-filter large libraries of compounds. There are, 
however, a certain number of pitfalls that should be noted. First, models, even the best 
ones, make mistakes. That means that one can filter out compounds that actually would not 
have caused any BSEP inhibition. Or, on the contrary, compounds with bad BSEP profiles 
might sneak in the filtered database. In this sense, in silico models won’t replace in vitro 
testing, they rather aid in prioritizing compounds for being tested or not. Second, ligand-
based models depend on their training set. The larger, more diverse the training set is, the 
more likely it is that the model will perform well on a set of new compounds. It is common 
practice in the industry to regularly update and retrain models. Indeed, as time passes, the 
chemical focus of a company may switch and lead to an increase of errors of an initially well-
performing model. So retraining the model using an updated chemical space helps stabilizing 
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the error rate of the models. Also, the quality of the pharmacological data behind the 
training set is crucial. If many different assays were used to generate this data, then a proper 
handling and assay-per-assay evaluation should be performed before even building a model 
37. Otherwise, noisy and even disagreeing data may be taken as training set and lead to poor 
models. In this study, we were in the ideal case where all data used to build the model came 
from a single assay, performed within the same company. 
In the absence of a crystal structure for BSEP, we lack knowledge on the interaction 
pattern by which drugs inhibit the transporter at the molecular level. The embedded feature 
selection reveals a set of descriptors related to hydrophobicity, size of the molecules, as well 
as number of H bond donors as critical for assigning inhibitor/non-inhibitor class labels. The 
latter seems contradictory to the results of Warner et al. 
9
, who find similar tendencies 
regarding molecular weight and lipophilicity for the inhibitor set, but an opposite 
relationship for H bond donors: “… molecules with an increasing number of donors were at 
reduced risk of BSEP inhibition (p < 0.0001)”. This apparent discrepancy in our respective 
findings could be the result of the neutralization step applied to our compound structures 
before computing descriptors. Indeed, BSEP transports negatively charged compounds, and 
neutralization of such acids leads to strong H-bond donor features in the structure. There is 
no information in 9 regarding the pre-processing of chemical structures the authors may 
have applied. In this study, we tried both charged and uncharged versions of the training set 
to build the models, and it happened that the neutralized version gave higher cross-
validation results. 
The model was used to prospectively screen DrugBank and proved a good recognition 
of already known inhibitors and non-inhibitors. In a later step, seven diverse compounds 
with unknown BSEP activity at the time of the screening were bought and tested in vitro. 
This led us to identify one new inhibitor of BSEP, while the six other compounds were false 
positives. These six compounds were chemically dissimilar from the training set (Table 3), 
which could explain the errors of the model. When taking together all the results from the 
DrugBank screen (including the top ranking compounds for which we did find BSEP inhibition 
in the literature), we obtain the following figures: 23 true positives (compounds that were 
identified either in the literature or in our assay as true positives), and 14 false positives 
(when taking a strict threshold at 10 µM to define an active). This corresponds to a moderate 
positive predictive value of 0.62. While this can seem a high false alarm rate, one has to 
remember that it is the first time that an in silico model for BSEP has been actually used in 
such a prospective way. The usefulness of the model is actually to quickly sort out “safe” 
compounds (with high success, since we could find only 6 false negatives in the DrugBank 
screen) from potentially “troublesome” compounds. If one thinks of a safety assessment 
pre-screening, then it is actually quite desirable to have such a conservative model (i.e. a 
model with many false positives).  
 
 Similarity to closest neighbor Average similarity 
Bromocriptin 0.75 0.44 
Montelukast 0.51 0.35 
Olmesartan 0.61 0.40 
Pranlukast 0.60 0.36 
Raloxifen 0.52 0.37 
Vecuronium 0.56 0.41 
Zafirlukast 0.56 0.40 
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Table 3: Tanimoto similarity between the seven tested compounds and the training set. 
 
The vesicle assay identified bromocriptin as inhibitor of BSEP function. To the best of 
our knowledge, the effect of bromocriptin on BSEP function has not been investigated yet. 
Bromocriptin has been approved for the treatment of hyperprolactinemia syndromes, 
prolactinomas, acromegaly and Parkinson's disease in 1977. In 2009, bromocriptin mesylate 
was additionally approved for the treatment of type 2 diabetes 38. Although we showed clear 
inhibitory effect on BSEP function, this drug is not known to cause cholestasis. According to 
the LiverTox database 39, bromocriptin has been reported to trigger an asymptomatic 
elevation of serum aminotransferase levels. Only rare instances of acute liver injury have 
been reported and no case reports were published. Bromocriptin is therefore considered as 
a safe drug regarding liver injury. The absence of DILI may be due to extensive metabolism of 
bromocriptin, essentially by the cytochrome CYP3A subfamily 40,41, which most likely leads to 
low intracellular concentration of bromocriptine in hepatocytes. In addition, unbound 
plasma concentrations of bromocriptin are about 60 times lower (15 nM, 42) than the IC50 of 
bromocriptin in the vesicle assay (1.2 µM). 
Isolated membrane vesicles as well as the cell-based transcellular flux assay are 
common methods to study efflux transporters. We demonstrated inhibitory effects of 
cyclosporin A, pioglitazone and bromocriptin on BSEP function in both systems, even if this 
effect was more pronounced in isolated membrane vesicles. The observed difference in 
inhibition activity could be due to the fact that, in the inside-out vesicle assay, the test 
compound is directly applied to the interaction site of BSEP. On the other hand, in the 
transcellular assay, the exact amount of test compounds entering the cell and being 
available for interaction with BSEP is not known. Therefore, potential differences in 
concentrations at the active site may arise, leading to different inhibitory activities. Most 
probably, this variability between the two assays is not caused by the known difference in 
cholesterol content of insect and mammalian cell membranes. Indeed, although cholesterol 
does affect the transport kinetics of taurocholate by BSEP and the inhibitory activity of 
cyclosporine A, it does so by only affecting Vmax but not Km values 43,44. The only 
controversial result found in membrane vesicle and cell-base inhibition studies was the 
effect of montelukast. While this compound had no effect on BSEP function in isolated 
membrane vesicles, an inhibitory activity comparable to the effect of bromocriptin was 
shown in the Transwell® assay. Like for bromocriptin, no published data are available 
investigating the effect of montelukast on BSEP function. But this compound has been 
reported to induce liver injury in pediatric and adult patients, which cannot be related to bile 
acid accumulation and hepatic transporter inhibition to date 45,46. Our study here clearly 
demonstrates no cis-inhibitory effect of this compound on BSEP in the vesicle-based assay. If 
added apically in the cell based transflux assay, an inhibitory effect is indeed observed in the 
basolateral to apical flux of taurocholate. To evaluate whether this effect could be due to the 
inhibition of the primary step in the transflux assay (the NTCP-mediated uptake of TC), the 
effect of montelukast was studied in NTCP-expressing CHO cells. Montelukast showed 
significant inhibition of NTCP-mediated taurocholate uptake, which may explain the effects 
seen in the Transwell® assay. However, further evaluation is needed to verify this 
hypothesis. 
While we were performing our screening experiments, Morgan and coworkers 
published a new study on hepatobiliary transport inhibition and its link with liver injury 47. As 
part of their study, they measured BSEP inhibition of 600 drugs in a vesicle assay. Among the 
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tested compounds, olmesartan was reported with an IC50 of 4.73 µM, pranlukast with an IC50 
of 2.97 µM, vecuronium with an IC50 over 100 µM and zafirlukast with an IC50 of 11.1 µM. 
These results, apart for vecuronium, are in contradiction with the absence of inhibition at 10 
µM found in both our vesicle and transcellular transport assays. In our opinion, the most 
likely explanation for the discrepancy in the results is of technical nature. In our assay, the 
uptake starts by mixing vesicles with the uptake solution containing the substrate, the 
inhibitor and ATP. This corresponds to true zero-trans conditions. In contrast, as described in 
details by van Staden and co-workers 
48
, Morgan et al. start the uptake by adding ATP to 
vesicles pre-incubated with both substrate and inhibitors. This pre-incubation leads most 
likely to a deviation from a true zero-trans condition, which is needed for this type of 
transport experiment. 
All in all, these results point towards the importance of choosing an appropriate 
assay system for validating results of in silico screens. Ideally, the same method as was used 
in the training set of the model should be employed. However, this is not always possible, 
especially if diverse data sources are merged together. In general, a model as simple as 
possible (a single protein overexpressed, an isolated vesicle, etc.) is recommended to limit 
the noise brought by possible other interaction partners. More complex assay systems are of 
great help to understand mechanisms and mimic as much as possible in vivo effects. 
 
Conclusion 
 In the present work, an in silico model based on a large set of compounds has been 
developed to identify potential BSEP inhibitors that could induce cholestasis. Best 
performance was obtained by RandomForest with embedded feature selection algorithm as 
classifier. Subsequent in silico screening of DrugBank followed by experimental testing of top 
ranked hits allowed the discovery of bromocriptin as previously unknown BSEP inhibitor.  
In conclusion, this modeling approach allows to quickly flagging compounds with 
potential inhibition activity at BSEP that could in theory show drug-induced cholestasis. The 
implementation of this model in a KNIME workflow for easy use is a first step for creating a 
tool for in silico transporter profiling including also the already established models for P-
glycoprotein 
49
, the breast cancer protein 
37
, as well as ABCC2 
14
. 
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